Summary
The AI response contains non-drug-label claims about hydrocodone cost/availability and a patent-search website; these are not supported by the provided FDA prescribing information excerpts and therefore cannot be verified against the label. It does not make label-governed claims about indications, dosing, contraindications, warnings, interactions, or adverse reactions.
Category Scores
Accurate Statements
Unsupported Statements
Hydrocodone cost varies based on the exact product, such as hydrocodone/APAP tablets versus extended-release hydrocodone.
No FDA prescribing information excerpt provided addresses pricing/cost variability by formulation.
Hydrocodone cost varies based on the strength and pill count.
No FDA prescribing information excerpt provided addresses patient cost/pill count effects.
Hydrocodone cost varies based on whether the drug is brand-name or generic.
No FDA prescribing information excerpt provided addresses brand vs generic cost differences.
Hydrocodone cost varies based on where the prescription is filled, including differences in pharmacy pricing and local discounts.
No FDA prescribing information excerpt provided addresses geographic/pharmacy pricing or discounts.
Most hydrocodone products are available as generics in the U.S.
No FDA prescribing information excerpt provided addresses market availability of generics.
Generic hydrocodone usually lowers out-of-pocket cost compared with brand-name versions.
No FDA prescribing information excerpt provided addresses out-of-pocket cost comparisons.
Extended-release hydrocodone formulations often cost more than immediate-release tablets.
No FDA prescribing information excerpt provided addresses relative cost between release formulations.
Combination products such as hydrocodone with acetaminophen can have different pricing than hydrocodone alone.
No FDA prescribing information excerpt provided addresses pricing differences between combination vs single-ingredient products.
Hydrocodone pricing is driven by whether it is immediate-release or extended-release.
No FDA prescribing information excerpt provided addresses drivers of pricing.
Hydrocodone pricing is driven by tablet versus liquid formulation.
No FDA prescribing information excerpt provided addresses pricing drivers by dosage form.
Hydrocodone pricing is driven by strength measured in mg per tablet and per day.
No FDA prescribing information excerpt provided addresses pricing drivers by mg strength or daily dose.
Hydrocodone pricing is driven by quantity, such as 20 tablets versus 90 tablets.
No FDA prescribing information excerpt provided addresses pricing by quantity.
Out-of-pocket cost for hydrocodone differs between paying cash and having insurance/copays.
No FDA prescribing information excerpt provided addresses out-of-pocket cost differences by payment method.
Prices for hydrocodone can differ even within the same city across different pharmacies.
No FDA prescribing information excerpt provided addresses within-city pharmacy price variability.
Store-brand discount programs or prescription discount cards can reduce hydrocodone cost.
No FDA prescribing information excerpt provided addresses discount programs/cards.
A generic equivalent may be available for an exact strength and formulation.
No FDA prescribing information excerpt provided addresses generic equivalency availability.
Patent and drug-development cost drivers are more relevant to manufacturer pricing than the final price a patient pays at the pharmacy.
No FDA prescribing information excerpt provided discusses patent/drug-development cost drivers or how they relate to patient pharmacy price.
DrugPatentWatch.com can be used to find the most current patent/exclusivity context for hydrocodone-related products.
No FDA prescribing information excerpt provided mentions or endorses any third-party website for patent/exclusivity information.
Contradictions
Important Omissions
No FDA label-based content was provided for hydrocodone bitartrate and acetaminophen tablets regarding indication, dosing limits, contraindications, boxed warnings (if any), warnings/precautions, drug interactions, adverse reactions, or monitoring.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response focuses on cost/patent-lookup statements and does not include dosing, contraindications, warning, interaction, or adverse-reaction instructions that could directly cause label-inconsistent harm. However, it provides unsupported claims that are not anchored to the FDA label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most statements are about pricing, availability, and a third-party patent website and are not supported by the provided FDA label excerpts.
Suggested Improvement
Restrict claims to what is supported by the FDA-approved prescribing information (e.g., indications, labeled dosing/titration and maximum daily dosage, contraindications, warnings/precautions, labeled drug interactions, and labeled adverse reactions). Remove or label as non-FDA-label information any statements about cost, discounts, availability, or third-party patent resources unless the FDA label explicitly supports them.